Comparative pharmacokinetics and bioavailability of brimonidine following ocular and dermal administration of brimonidine tartrate ophthalmic solution and gel in patients with moderate-to-severe facial erythema associated with rosacea

British Journal of Dermatology

Volumn 171, Issue 1, 2014, Pages 162-169

  Benkali, K ^a   Leoni, M ^b   Rony, F ^a   Bouer, R ^a   Fernando, A ^b   Graeber, M ^b   Wagner, N ^a  

^a Galderma R and D   (France)

^b Galderma RandD   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BRIMONIDINE; EYE DROPS; ALPHA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; GEL; QUINOXALINE DERIVATIVE;

ADULT; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE SEVERITY; DRUG ABSORPTION; DRUG ACCUMULATION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DOSE REGIMEN; DRUG EXPOSURE; FACE ERYTHEMA; FEMALE; GEL; HUMAN; MAJOR CLINICAL STUDY; MALE; MAXIMUM PLASMA CONCENTRATION; MULTICENTER STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; ROSACEA; STEADY STATE; SYSTEMIC THERAPY; TOPICAL TREATMENT; TREATMENT DURATION; BIOAVAILABILITY; BLOOD; CLINICAL TRIAL; COMPARATIVE STUDY; DRUG ADMINISTRATION; FACIAL DERMATOSES; INTRADERMAL DRUG ADMINISTRATION; METABOLISM;

ADMINISTRATION, CUTANEOUS; ADRENERGIC ALPHA-2 RECEPTOR AGONISTS; ADULT; AREA UNDER CURVE; BIOLOGICAL AVAILABILITY; DRUG ADMINISTRATION SCHEDULE; FACIAL DERMATOSES; FEMALE; GELS; HUMANS; MALE; OPHTHALMIC SOLUTIONS; QUINOXALINES; ROSACEA;

EID: 84904978248     PISSN: 00070963     EISSN: 13652133     Source Type: Journal    
DOI: 10.1111/bjd.12881     Document Type: Article

References (12)

1. Walters TR,. Development and use of brimonidine in treating acute and chronic elevations of intraocular pressure: a review of safety, efficacy, dose response, and dosing studies. Surv Ophthalmol 1996; 41 (Suppl. 1): S19-26.
2. Greenfield DS, Liebmann JM, Ritch R,. Brimonidine: a new alpha2-adrenoreceptor agonist for glaucoma treatment. J Glaucoma 1997; 6: 250-8.
3. Fowler J, Jarratt M, Moore A, et al,. Once-daily topical brimonidine tartrate gel 0.5% is a novel treatment for moderate to severe facial erythema of rosacea: results of two multicentre, randomized and vehicle-controlled studies. Br J Dermatol 2012; 166: 633-41.
4. Galderma Laboratories. Mirvaso Topical Gel, 0.33%. Fort Worth, TX: Galderma Laboratories, 2013.
5. Fowler J Jr, Jackson M, Moore A, et al,. Efficacy and safety of once-daily topical brimonidine tartrate gel 0.5% for the treatment of moderate to severe facial erythema of rosacea: results of two randomized, double-blind, and vehicle-controlled pivotal studies. J Drugs Dermatol 2013; 12: 650-6.
6. ® P. Irvine, CA: Allergan, 2011.
7. US Department of Health and Human Services, US Food and Drug Administration, Center for Drug Evaluation and Research. Acne vulgaris: developing drugs for treatment. Draft guidance. Available at: http://www.fda.gov/downloads/Drugs/&x2026;/Guidances/UCM071292.pdf (last accessed 6 March 2014).
8. Shah VP, Behl CR, Flynn GL, et al,. Principles and criteria in the development and optimization of topical therapeutic products. Skin Pharmacol 1993; 6: 72-80.
9. Allergan. FDA Drug Approval Package NDA21-262. Alphagan Clinical Pharmacology/Biopharmaceuticals Review. Irvine, CA: Allergan, 2001.
10. Crawford GH, Pelle MT, James WD,. Rosacea: I. Etiology, pathogenesis, and subtype classification. J Am Acad Dermatol 2004; 51: 327-41.
11. Pelle MT, Crawford GH, James WD,. Rosacea: II. Therapy. J Am Acad Dermatol 2004; 51: 499-512.
12. Wilkin J, Dahl M, Detmar M, et al,. Standard classification of rosacea: report of the National Rosacea Society Expert Committee on the Classification and Staging of Rosacea. J Am Acad Dermatol 2002; 46: 584-7.